Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR

Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology

Alec Vahanian, Helmut Baumgartner, Jeroen J. Bax et al. · European Heart Journal · 2006 · 3.6K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Methods in Molecular Biology

Vasanth V Ranade · American Journal of Therapeutics · 2009 · 2.8K citations

Life Sciences, Biology, Molecular Biology +8

Effect of <i>VKORC1</i> Haplotypes on Transcriptional Regulation and Warfarin Dose

Mark J. Rieder, Alex P. Reiner, Brian F. Gage et al. · New England Journal of Medicine · 2005 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Guruprasad P. Aithal, Christopher P. Day, Patrick Kesteven et al. · The Lancet · 1999 · 1.2K citations

Medicine, Pharmacokinetics, Pharmacology +12

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

Elizabeth Sconce, Tayyaba Khan, Hilary Wynne et al. · Blood · 2005 · 947 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17